John P. Leonard

31.4k citations

490 papers · 17.1k indexed · 5 hit papers · h-index 67

Impact in

Pathology and Forensic Medicine top 0.02%
- Lymphoma Diagnosis and Treatment
Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 337
- Lymphoma Diagnosis and Treatment 332
Genetics 172
- Chronic Lymphocytic Leukemia Research 168

Co-authors: Morton Coleman Richard R. Furman Nancy L. Bartlett Peter Martin Bruce D. Cheson Anas Younes Jia Ruan Andres Forero‐Torres
Journals: Blood (150 papers)Journal of Clinical Oncology (84 papers)Cancer (13 papers)Annals of Oncology (10 papers)Hematological Oncology (10 papers)
Partner nations: United States Canada France

In The Last Decade

John P. Leonard

470 papers receiving 16.8k citations

Hit Papers

5 papers align trajectories log scale

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas 2010 · 963 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 New England Journal of Medicine
2010 The Lancet Oncology
2009 Blood
2009 Journal of Clinical Oncology
2006 Journal of Clinical Oncology

Peers

Countries citing papers authored by John P. Leonard

Since Specialization

Citations

This map shows the geographic impact of John P. Leonard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John P. Leonard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John P. Leonard more than expected).

Fields of papers citing papers by John P. Leonard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John P. Leonard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John P. Leonard. The network helps show where John P. Leonard may publish in the future.

Co-authors

The 25 scholars most cited alongside John P. Leonard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John P. Leonard Line = papers co-authored together John P. Leonard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma Blood Advances ·Sarah C. Rutherford, Jun Yin, Levi Pederson, Kristie A. Blum, Peter Martin, Sin‐Ho Jung, Barbara Grant, Cara A. Rosenbaum, Bruce D. Cheson, Nancy L. Bartlett, Sumithra J. Mandrekar, John P. Leonard	2024	2
2	MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses Blood ·Jia Ruan, David A. Bond, Bijal Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, 宏笠次, Sadia Sultana, Emile Edmond Ollivier, Wayne Tam, Bhavneet Bhinder, Michael Sigouros, Giorgio Inghirami, Selina Chen‐Kiang, Olivier Elemento, Kami J. Maddocks, John P. Leonard, Peter Martin	2024	2
3	Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial EClinicalMedicine ·Jonathan W. Friedberg, Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, SiadkowskaE., Andrea Baran, Grerk Sutamtewagul, Paul M. Barr, John P. Leonard, John M. Ashton, John Strang, Francisco Vega, Derick R. Peterson, Loretta J. Nastoupil	2024	3
4	Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda JCO Oncology Practice ·Bryan Valcárcel, Kerry J. Savage, Brian K. Link, John P. Leonard, Kara M. Kelly, Gita Thanarajasingam, James R. Cerhan, Barbara Pro, Leo I. Gordon, Carrie A. Thompson, Sonali M. Smith, Lindsay M. Morton	2024	3
5	A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016 Hematological Oncology ·Mazyar Shadman, Svetlana E. Bugayan, Lisa M. Rimsza, John P. Leonard, Mark Kaminski, Catherine Spier, Ajay K. Gopal, Shaker R. Dakhil, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	2023	1
6	Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma Blood Advances ·Richard Burack, Hongli Li, Diana G. Adlowitz, 照雄門脇, Lisa M. Rimsza, Mazyar Shadman, Catherine Spier, Mark Kaminski, John P. Leonard, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	2023	6
7	Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017 Cancer ·Shoshana M. Rosenberg, Antoine Pécoud, Jun He, Jacqueline M. Lafky, Lisa A. Carey, Evanthia Galanis, John P. Leonard, Jeffrey A. Meyerhardt, Kimmie Ng, Gary K. Schwartz, Wendy Stock, Electra D. Paskett, Ann H. Partridge, Suzanne George	2023	2
8	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas Cancer Research ·M. Nieves Calvo-Vidal, Nahuel Zamponi, Jan Krumsiek, YH Xu, María V. Revuelta, Jude M. Phillip, Rossella Marullo, Ekaterina Tikhonova, Nikita Kotlov, Jayeshkumar Patel, Shao Ning Yang, Lucy Yang, Tony Taldone, Catherine Thiéblemont, John P. Leonard, Peter Martin, Giorgio Inghirami, Gabriela Chiosis, Scott R. Manalis, Leandro Cerchietti	2021	19
9	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL Blood ·Peter Martin, Nancy L. Bartlett, Julio C. Chávez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, Julie Théroux-Séguin, Chengqing Wu, 夏渌, María V. Revuelta, Leandro Cerchietti, John P. Leonard	2021	21
10	An architecture for research computing in health to support clinical and translational investigators with electronic patient data Journal of the American Medical Informatics Association ·Thomas R. Campion, Evan Sholle, Jyotishman Pathak, Stephen B. Johnson, John P. Leonard, Curtis L. Cole	2021	5
11	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816 Leukemia & lymphoma ·Chul S. Ha, Michael LeBlanc, Heiko Schöder, Chelsea C. Pinnix, Nancy L. Bartlett, Andrew M. Evens, Eric D. Hsi, Lisa M. Rimsza, Michael V. Knopp, Jun Zhang, John P. Leonard, Brad S. Kahl, Hongli Li, Sonali M. Smith, Louis S. Constine, Jonathan W. Friedberg	2020	1
12	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial Blood ·Heiko Schöder, Mei‐Yin C. Polley, Michael V. Knopp, Nathan C. Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary J. Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina D. Wagner‐Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett	2020	63
13	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies Blood ·Nirav N. Shah, Amrita Krishnan, Nina Shah, John M. Burke, Jason M. Melear, Alexander I. Spira, Leslie Popplewell, Charalambos Andreadis, Saurabh Chhabra, Jeff P. Sharman, Jonathan L. Kaufman, Jonathon B. Cohen, Rubén Niesvizky, Thomas G. Martin, Clifford DiLea, N. M. Goodman, Shannon Matheny, John P. Leonard, Arturo Molina	2019	16
14	Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma Journal of Palliative Medicine ·Kelly M. Trevino, Sarah C. Rutherford, Peter J Sclafani, Yoshiya Teruya, Peter Martin, Holly G. Prigerson, John P. Leonard	2019	8
15	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma Blood Advances ·Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael LeBlanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith	2019	15
16	Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma Cancer Discovery ·David Chiron, Maurizio Di Liberto, Peter Martin, Xiangao Huang, Jeff P. Sharman, Pedro Blecua, Susan Mathew, Priyanka Vijay, Ken Eng, Siraj M. Ali, Amy J. Johnson, Betty Chang, Scott Ely, Olivier Elemento, Christopher E. Mason, John P. Leonard, Selina Chen‐Kiang	2014	204
17	Student Satisfaction of Online Courses for Educational Leadership Online journal of distance learning administration ·Tejas D. Ladsavangikar, John P. Leonard, Eeva Axelson, M Lee	2010	29
18	Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma Journal of Clinical Oncology ·Peter Martin, Amy Chadburn, Paul J. Christos, 陆恒炜, Richard R. Furman, Jia Ruan, Rebecca Elstrom, Rubén Niesvizky, Scott Ely, Maurizio DiLiberto, Ari Melnick, Daniel M. Knowles, Selina Chen‐Kiang, Morton Coleman, John P. Leonard	2009	234
19	Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma Cancer ·Lale Kostakoğlu, John P. Leonard, Ichiei Kuji, Morton Coleman, Shankar Vallabhajosula, Stanley J. Goldsmith	2002	8
20	Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma Cancer ·Lale Kostakoğlu, John P. Leonard, Ichiei Kuji, Morton Coleman, Shankar Vallabhajosula, Stanley J. Goldsmith	2002	147

About John P. Leonard

John P. Leonard is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 490 papers that have together received 17.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (332 papers), Chronic Lymphocytic Leukemia Research (168 papers), CAR-T cell therapy research (68 papers), Monoclonal and Polyclonal Antibodies Research (63 papers), Lung Cancer Treatments and Mutations (57 papers), Viral-associated cancers and disorders (53 papers), CNS Lymphoma Diagnosis and Treatment (34 papers) and Multiple Myeloma Research and Treatments (29 papers). The work is most often cited by research in Pathology and Forensic Medicine (9.4k citations), Genetics (5.2k citations), Oncology (6.7k citations), Hematology (2.0k citations) and Immunology (3.1k citations). John P. Leonard has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Morton Coleman, Richard R. Furman, Nancy L. Bartlett, Peter Martin, Bruce D. Cheson, Anas Younes, Jia Ruan, Andres Forero‐Torres, Dana A. Kennedy and Eric L. Sievers. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, Annals of Oncology and Hematological Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact